{"id":288,"date":"2026-03-31T16:18:19","date_gmt":"2026-03-31T16:18:19","guid":{"rendered":"https:\/\/kstories.kr\/en\/tec260331010-en\/"},"modified":"2026-03-31T16:18:19","modified_gmt":"2026-03-31T16:18:19","slug":"tec260331010-en","status":"publish","type":"post","link":"https:\/\/kstories.kr\/en\/tec260331010-en\/","title":{"rendered":"GC Cell Files CAR-NK Technology Patent, Expanding Possibilities for Solid Cancer Treatment"},"content":{"rendered":"
\n
GC Cell Files Patent Application for CAR-NK Immunotherapy Technology Targeting Solid Cancers<\/div>\n
\"Image\"<\/div>\n

GC Cell (Co-CEOs Kim Jae-wang and Won Sung-yong) announced on the 31st that it has filed a patent application related to immunotherapy for the treatment of solid cancers. This is a pipeline developed based on GC Cell’s CAR-NK platform, targeting CLDN18.2, and is considered a significant expansion of its applicability to the field of solid cancers.<\/p>\n

Patent Application for Solid Cancer-Targeting CAR-NK Technology<\/h2>\n

GC Cell recently filed a patent application for immunotherapy technology aimed at treating solid cancers. This patent was developed by utilizing GC Cell’s proprietary CAR-NK (Chimeric Antigen Receptor-Natural Killer cell) platform to target a specific protein, CLDN18.2.<\/p>\n

This technology is highly significant because it extends beyond the limitations of existing immunotherapies, which primarily targeted blood cancers, to expand applicability to the challenging field of solid cancers. Through this patent, GC Cell aims to gain a competitive edge in the development of solid cancer treatments.<\/p>\n

CLDN18.2 Protein Expressed in Major Solid Cancers<\/h2>\n

CLDN18.2, the key target of this technology, is known to be a protein commonly expressed in various solid cancers, including gastric cancer, pancreatic cancer, and esophageal cancer. This protein has been identified as playing a crucial role in cancer cell growth and is currently attracting significant attention as a new therapeutic target in the global pharmaceutical and biotechnology industry.<\/p>\n

The development of therapies targeting CLDN18.2 is expected to offer new treatment options for patients with solid cancers. GC Cell’s patent application is analyzed to be in line with these global research trends.<\/p>\n

Strengths and Expandability of CAR-NK Therapies<\/h2>\n

Unlike CAR-T (Chimeric Antigen Receptor-T cell) therapies, which use a patient’s own cells, CAR-NK therapies utilize cells from healthy donors. This characteristic offers the advantage of being developed as a mass-producible, off-the-shelf therapy.<\/p>\n

Furthermore, high safety is expected based on the innate immune characteristics of NK cells. It is regarded as an alternative that can contribute to reducing treatment costs and improving patient accessibility through efficiency in manufacturing and supply.<\/p>\n

Strengthening Global Competitiveness and Continued R&D<\/h2>\n

Won Sung-yong, CEO of GC Cell, stated, \u201cThis patent is one of the continuous achievements in the research and development of our CAR-NK platform-based solid cancer pipeline.\u201d<\/p>\n

GC Cell announced its plan to continue pursuing relevant research and development to further strengthen its global competitiveness.<\/p>\n

Through this patent application, GC Cell is expected to secure a leading position in the field of solid cancer immunotherapy and provide innovative treatment alternatives to solid cancer patients worldwide. GC Cell plans to continue leading the next-generation cell therapy market through ongoing research and development.<\/p>\n

English-Korean version<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GC Cell Files Patent Application for CAR-NK Immunotherapy Technology Targeting Solid Cancers GC Cell (Co-CEOs Kim Jae-wang and Won Sung-yong)…<\/p>\n","protected":false},"author":10,"featured_media":287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[295,294,297,296],"class_list":["post-288","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech-economy","tag-car-nk","tag-gc-cell","tag-immunotherapy","tag-solid-cancer"],"_links":{"self":[{"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/posts\/288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/comments?post=288"}],"version-history":[{"count":0,"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/posts\/288\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/media\/287"}],"wp:attachment":[{"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/media?parent=288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/categories?post=288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kstories.kr\/en\/wp-json\/wp\/v2\/tags?post=288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}